{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T14:06:59Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 30.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07c30-5026-7f93-a7f0-2a3a4b82d30e\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: dopamine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 546 things:\n# Batch 003: 1001 registe", "usd": 0.0, "recall": true }, "codex": { "seconds": 83.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07c30-500a-78d2-962e-a21f3e34182d\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: dopamine\nRegistry id: vr.tr.dopamine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nContex" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:43:09+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:26+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q170304", "registryId": "vr.tr.dopamine", "name": "dopamine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q170304/", "model": { "registry_id": "vr.tr.dopamine", "name": "dopamine", "purpose": "Enable an AI agent to identify dopamine, assess its chemical and biological state, and determine which handling, measurement or use decisions the available evidence supports.", "definition": "Dopamine is the catecholamine 3,4-dihydroxyphenethylamine, an endogenous signalling molecule that acts as a neurotransmitter and peripheral mediator and is a biosynthetic precursor of noradrenaline and adrenaline.", "scope_statement": "This model owns dopamine as the chemical substance registered as vr.tr.dopamine in PHY / PHY.MAT, including distinctions among molecular identity, protonation, salt form, sample quality and biological context; preparations and biological systems are related entities.", "in_scope": [ "Dopamine molecular identity and differentiation from related catecholamines and precursors", "Free-base, protonated and salt-form relationships, with form-specific identifiers", "Sample composition, purity, concentration and degradation state", "Physical properties and stability under explicitly recorded conditions", "Dopamine occurrence, biochemical transformations and receptor interactions", "Evidence supporting analytical identification, safe handling and permitted use" ], "out_of_scope": [ "Finished medicines, their formulations, prescribing and patient-specific dosing", "Complete models of neurons, synapses, organs or dopaminergic pathways", "Diseases, diagnoses and treatment plans associated with dopamine signalling", "Reward, pleasure, motivation or addiction as psychological phenomena", "Manufacturing processes and analytical instruments as independent things", "Related substances such as levodopa, norepinephrine and dopamine-derived polymers" ], "distinguishing_features": [ "The neutral parent molecule has a catechol ring bearing a two-carbon chain terminating in a primary amine; its molecular formula is C8H11NO2.", "Unlike levodopa, dopamine lacks the amino-acid carboxyl group; precursor and product must remain distinct identities.", "Unlike norepinephrine, dopamine lacks a hydroxyl group on the side-chain carbon adjacent to the aromatic ring.", "A dopamine salt contains a counterion, so its formula mass and reported mass concentration cannot automatically be treated as those of dopamine free base.", "Dopamine identity requires chemical evidence; a sample's biological effect or description as a 'reward chemical' is insufficient." ], "characteristics": [ { "name": "Chemical identity and identifier scope", "kind": "category", "unit_or_values": "Structure representation; molecular formula; verified CAS, PubChem CID and EC identifiers where applicable, each tied to a specific form", "why_it_matters": "Prevents identifiers for the neutral parent, a salt or a commercial preparation from being treated as interchangeable." }, { "name": "Chemical form", "kind": "state", "unit_or_values": "Neutral parent, protonated species or named salt; counterion and hydration state where established", "why_it_matters": "Determines the interpretation of mass, solubility, preparation instructions and reference properties." }, { "name": "Dopamine content", "kind": "measurement", "unit_or_values": "mol/L, mg/mL or mass fraction, with free-base or salt basis explicitly stated", "why_it_matters": "Makes concentration comparisons and quantity conversions reproducible." }, { "name": "Purity and impurity profile", "kind": "measurement", "unit_or_values": "Assay percentage with method and basis; identified impurities and their concentrations", "why_it_matters": "Distinguishes usable dopamine content from water, counterions, residual reagents and degradation products." }, { "name": "Physical state and reference properties", "kind": "state", "unit_or_values": "Solid or dissolved state; solvent; temperature in °C; pressure in kPa; solubility in g/L; melting or decomposition observations in °C", "why_it_matters": "Prevents condition-dependent or form-specific properties from becoming universal constants." }, { "name": "Chemical environment", "kind": "measurement", "unit_or_values": "pH, temperature in °C, elapsed time, light exposure and oxygen conditions", "why_it_matters": "Supports interpretation of protonation, oxidation risk and comparability between samples." }, { "name": "Biological location", "kind": "relation", "unit_or_values": "Organism, tissue, cell and compartment; endogenous or introduced origin", "why_it_matters": "A tissue measurement, extracellular measurement and administered quantity describe different biological situations." }, { "name": "Interaction or transformation", "kind": "relation", "unit_or_values": "Named receptor, transporter, enzyme, precursor or metabolite, with direction and supporting evidence", "why_it_matters": "Connects dopamine to biological mechanisms without assigning it a single universal effect." }, { "name": "Analytical evidence", "kind": "relation", "unit_or_values": "Method, reference standard, sample preparation, selectivity, detection limits and measurement uncertainty", "why_it_matters": "Determines whether a reported signal establishes dopamine identity or merely suggests its presence." }, { "name": "Hazard and use status", "kind": "category", "unit_or_values": "Form-specific safety classification, jurisdiction, source date, grade and documented use restrictions", "why_it_matters": "Supports handling and use decisions without transferring claims between research materials and pharmaceutical products." } ], "affordances": [ "Resolve a named material or analytical result to dopamine and its specific chemical form.", "Convert reported quantities between salt and dopamine-equivalent bases when composition and assay are established.", "Assess whether storage history and analytical evidence support continued sample use.", "Select an identification or quantification approach appropriate to the matrix and expected interferents.", "Relate dopamine measurements to specified biological compartments and mechanisms.", "Determine which handling or use decisions are supported by current form-specific documentation." ], "agent_conduct": { "may": [ "Explain dopamine's roles in the body and as a medicine from scientific sources.", "Correct popular misconceptions about dopamine with evidence." ], "must_not": [ "Present dopamine detox or dopamine hacking claims as established science.", "Advise a person on medicines that act on dopamine in place of their clinician.", "Make claims about a person's brain chemistry from their behaviour." ], "requires_human": [ "Any change to a patient's dopamine-acting medication." ] }, "ethics": { "considerations": [ "Popular myths about dopamine are used to sell products and self-help schemes.", "People with Parkinson's disease or psychiatric conditions rely on accurate information." ], "affected_parties": [ "Patients", "People seeking self-help", "Clinicians" ] }, "owners": { "steward": "Nobody owns the molecule; medicines regulators license dopamine as a drug.", "master_systems": [] }, "failure_modes_and_hazards": [ "As a drug it can cause dangerous heart rhythm and blood pressure changes." ], "what_it_is_for": [ "Dopamine occurs in nervous tissue and peripheral biological systems, where it participates in chemical signalling.", "It is studied in neuroscience, physiology and analytical laboratories to investigate signalling pathways and measure biological samples.", "Pharmaceutical preparations are encountered in clinical settings for specific circulatory indications." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns medicinal dopamine the code C01CA04." ], "facets_not_applicable": { "recognition": "Dopamine molecules cannot be visually perceived, and the appearance of a bulk material or solution does not establish its chemical identity." } }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q170304: dopamine", "url": "https://www.wikidata.org/wiki/Q170304", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Dopamine", "url": "https://en.wikipedia.org/wiki/Dopamine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "dopamine-identity-and-form", "name": "Dopamine identity and form", "description": "Establishes the dopamine parent structure and the exact form represented by a material record.", "rationale": "Dopamine, its salts and neighbouring catecholamines are readily conflated in names, identifiers and quantity reporting.", "layers": [ { "id": "parent-structure", "name": "Parent structure", "description": "Defines structural recognition and exclusion of related compounds.", "findings": [ { "id": "catechol-ethylamine-identity", "name": "Catechol ethylamine identity", "description": "Record structural evidence distinguishing dopamine from levodopa, norepinephrine and other similarly named substances.", "questions": [ { "text": "Which verified structure and identifiers establish that this record denotes dopamine?", "kind": "definition", "id": "catechol-ethylamine-identity-q01" }, { "text": "Which structural or analytical feature excludes levodopa and norepinephrine from this identification?", "kind": "boundary", "id": "catechol-ethylamine-identity-q02" } ] } ] }, { "id": "salt-and-protonation", "name": "Salt and protonation", "description": "Separates parent identity from counterions and condition-dependent species.", "findings": [ { "id": "form-specific-quantity-basis", "name": "Form-specific quantity basis", "description": "Record the counterion, stoichiometry, hydration and reporting basis needed to interpret a dopamine quantity.", "questions": [ { "text": "Does the material contain dopamine free base or a specified salt, and what establishes its composition?", "kind": "definition", "id": "form-specific-quantity-basis-q01" }, { "text": "Is the reported mass or concentration expressed as dopamine equivalent or as the complete salt?", "kind": "measurement", "id": "form-specific-quantity-basis-q02" }, { "text": "Which protonation assumptions are justified by the solvent and pH?", "kind": "boundary", "id": "form-specific-quantity-basis-q03" } ] } ] } ] }, { "id": "dopamine-sample-quality", "name": "Dopamine sample quality", "description": "Captures composition, physical properties and evidence that a sample remains suitable for its intended task.", "rationale": "Nominal dopamine content alone does not establish purity, physical behaviour or fitness for use.", "layers": [ { "id": "assay-and-grade", "name": "Assay and grade", "description": "Records dopamine content and the meaning of supplier or laboratory quality claims.", "findings": [ { "id": "usable-dopamine-content", "name": "Usable dopamine content", "description": "Distinguish measured dopamine content from chromatographic area purity, water content and grade labels.", "questions": [ { "text": "What assay method and calculation basis support the stated dopamine purity?", "kind": "measurement", "id": "usable-dopamine-content-q01" }, { "text": "Which lot-specific certificate or laboratory record establishes impurities, water content and grade?", "kind": "provenance", "id": "usable-dopamine-content-q02" } ] } ] }, { "id": "physical-properties-and-degradation", "name": "Physical properties and degradation", "description": "Connects form-specific properties and oxidation evidence to sample history.", "findings": [ { "id": "condition-dependent-integrity", "name": "Condition-dependent integrity", "description": "Record solvent, pH, oxygen, light, temperature and time alongside evidence of dopamine integrity or degradation.", "questions": [ { "text": "Which solubility and thermal-transition measurements apply to this exact form, and do they report decomposition?", "kind": "measurement", "id": "condition-dependent-integrity-q01" }, { "text": "What analytical evidence distinguishes intact dopamine from oxidation products, beyond a change in colour?", "kind": "measurement", "id": "condition-dependent-integrity-q02" }, { "text": "What validated storage or preparation conditions support using this sample for the intended task?", "kind": "action", "id": "condition-dependent-integrity-q03" } ] } ] } ] }, { "id": "dopamine-biological-context", "name": "Dopamine biological context", "description": "Places dopamine in defined compartments, transformations and molecular interactions.", "rationale": "The significance of dopamine depends on where it is measured and which mechanism is under examination.", "layers": [ { "id": "compartments-and-turnover", "name": "Compartments and turnover", "description": "Records biological location, origin and production or removal relationships.", "findings": [ { "id": "localized-dopamine-pool", "name": "Localized dopamine pool", "description": "Treat each biological dopamine measurement as belonging to a specified compartment and sampling interval.", "questions": [ { "text": "Which organism, tissue and intracellular or extracellular compartment does the observation represent?", "kind": "boundary", "id": "localized-dopamine-pool-q01" }, { "text": "What evidence links this dopamine pool to precursor conversion, release, uptake or metabolism?", "kind": "provenance", "id": "localized-dopamine-pool-q02" } ] } ] }, { "id": "receptor-and-transporter-relations", "name": "Receptor and transporter relations", "description": "Connects dopamine to named molecular targets and bounded experimental outcomes.", "findings": [ { "id": "contextualized-target-effect", "name": "Contextualized target effect", "description": "Separate dopamine concentration, target engagement and downstream effect as distinct observations.", "questions": [ { "text": "Which dopamine receptor subtype or transporter is implicated, and by what evidence?", "kind": "provenance", "id": "contextualized-target-effect-q01" }, { "text": "Under which concentration, exposure duration and experimental conditions was the interaction measured?", "kind": "measurement", "id": "contextualized-target-effect-q02" }, { "text": "Which claimed behavioural or physiological conclusions exceed what this molecular observation establishes?", "kind": "boundary", "id": "contextualized-target-effect-q03" } ] } ] } ] }, { "id": "dopamine-analytical-evidence", "name": "Dopamine analytical evidence", "description": "Defines what supports identifying and quantifying dopamine in a particular matrix.", "rationale": "Related catecholamines, matrix interference and sample degradation can undermine apparent dopamine measurements.", "layers": [ { "id": "identification-selectivity", "name": "Identification selectivity", "description": "Evaluates whether the analytical method separates dopamine from plausible alternatives.", "findings": [ { "id": "dopamine-specific-signal", "name": "Dopamine-specific signal", "description": "Record the reference comparison and selectivity evidence behind an assigned dopamine signal.", "questions": [ { "text": "Which reference standard and analytical features support assigning the observed signal to dopamine?", "kind": "provenance", "id": "dopamine-specific-signal-q01" }, { "text": "How does the method distinguish dopamine from related catecholamines, oxidation products and matrix interferents?", "kind": "measurement", "id": "dopamine-specific-signal-q02" } ] } ] }, { "id": "quantification-and-preservation", "name": "Quantification and preservation", "description": "Captures calibration, recovery and changes between collection and measurement.", "findings": [ { "id": "defensible-dopamine-concentration", "name": "Defensible dopamine concentration", "description": "Require a concentration result to carry its matrix, calibration basis, uncertainty and sample-preservation history.", "questions": [ { "text": "What calibration range, recovery, detection limit and uncertainty apply to this dopamine result?", "kind": "measurement", "id": "defensible-dopamine-concentration-q01" }, { "text": "How were collection, stabilisation and storage validated against dopamine loss or transformation?", "kind": "provenance", "id": "defensible-dopamine-concentration-q02" }, { "text": "Does the result represent free dopamine, a fraction released by sample treatment or another explicitly defined analyte pool?", "kind": "boundary", "id": "defensible-dopamine-concentration-q03" } ] } ] } ] }, { "id": "dopamine-handling-and-use", "name": "Dopamine handling and use", "description": "Links the exact dopamine material to supported handling practices and use qualifications.", "rationale": "Biological activity and chemical identity do not establish that a particular lot is safe or qualified for a proposed use.", "layers": [ { "id": "form-specific-hazards", "name": "Form-specific hazards", "description": "Records applicable safety evidence for the actual solid or solution.", "findings": [ { "id": "documented-exposure-controls", "name": "Documented exposure controls", "description": "Tie hazard classifications and handling controls to chemical form, concentration and current documentation.", "questions": [ { "text": "Which current safety data sheet and jurisdiction-specific classification apply to this dopamine material?", "kind": "provenance", "id": "documented-exposure-controls-q01" }, { "text": "Which controls and disposal instructions follow from its form, solvent, concentration and documented hazards?", "kind": "action", "id": "documented-exposure-controls-q02" }, { "text": "Is a substance-specific exposure limit documented, or is that information unavailable?", "kind": "provenance", "id": "documented-exposure-controls-q03" } ] } ] }, { "id": "qualified-use-boundaries", "name": "Qualified use boundaries", "description": "Separates research suitability from pharmaceutical and other regulated use requirements.", "findings": [ { "id": "lot-to-use-qualification", "name": "Lot-to-use qualification", "description": "Record evidence connecting this dopamine lot to an intended use while linking product-level decisions to the relevant neighbouring model.", "questions": [ { "text": "Which lot specifications and quality records establish suitability for the proposed analytical, research or manufacturing use?", "kind": "action", "id": "lot-to-use-qualification-q01" }, { "text": "Which decisions require a linked formulation, medicinal-product or clinical model rather than this dopamine substance model?", "kind": "boundary", "id": "lot-to-use-qualification-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This describes the chemical substance and its biological roles; pharmaceutical products require separate formulation, purity and sterility information.", "Identifiers and molar masses are recalled rather than checked against source records.", "Verify form-specific thermal properties, solubility, hazard classification, exposure limits and applicable pharmacopoeial requirements before adding them." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Dopamine free base", "Dopamine hydrochloride" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "51-61-6", "note": "Dopamine free base." }, { "scheme": "PubChem CID", "value_or_pattern": "681", "note": "Dopamine." }, { "scheme": "CAS Registry Number", "value_or_pattern": "62-31-7", "note": "Dopamine hydrochloride; distinct from the free base." }, { "scheme": "Molecular formula", "value_or_pattern": "C8H11NO2", "note": "Neutral dopamine; this formula does not include a hydrochloride counterion." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Endogenous neurotransmission involved in movement, motivation, reinforcement learning and other functions.", "Physiological inhibition of prolactin secretion.", "Intravenous pharmaceutical use to support circulation in selected clinical circumstances.", "Research reagent for studying catecholamine receptors, transporters and metabolism.", "Starting material for polydopamine coatings used in materials research." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of dopamine free base", "typical_range": "153.18", "unit": "g/mol" }, { "quantity": "Molar mass of anhydrous dopamine hydrochloride", "typical_range": "189.64", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Oxidation in solution can change composition and produce coloured products; stability depends on pH, oxygen, light and storage conditions.", "Confusing free-base mass with hydrochloride-salt mass causes concentration errors.", "Administered dopamine can cause arrhythmias and excessive vasoconstriction.", "Extravasation of pharmaceutical dopamine can cause local tissue ischaemia and necrosis.", "Research-grade material is not interchangeable with a sterile pharmaceutical formulation." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Levodopa", "difference": "Levodopa is an amino acid precursor converted to dopamine by decarboxylation; unlike dopamine, it crosses the blood-brain barrier sufficiently for central replacement therapy." }, { "name": "Noradrenaline", "difference": "Noradrenaline has an additional hydroxyl group on the side chain and is formed from dopamine by dopamine beta-hydroxylase." }, { "name": "Tyramine", "difference": "Tyramine has one phenolic hydroxyl group, whereas dopamine has two adjacent phenolic hydroxyl groups." }, { "name": "Dopamine receptor", "difference": "A dopamine receptor is a protein that responds to dopamine, not the chemical messenger itself." }, { "name": "Polydopamine", "difference": "Polydopamine is a heterogeneous material formed through dopamine oxidation and subsequent reactions, not molecular dopamine." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of dopamine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative records establish CAS, PubChem CID and EC mappings for the dopamine parent and relevant salts without conflating their identities?", "Which reliable measurements establish form-specific solubility, melting or decomposition behaviour, and whether a meaningful boiling-point value is available?", "What validated stability windows apply across relevant solvents, pH values, oxygen exposure, light conditions and temperatures?", "Which current hazard classifications, exposure limits and use restrictions apply to each intended material form and jurisdiction?", "Which analytical methods provide adequate dopamine selectivity and preservation for the intended biological or manufactured-material matrices?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 32 } }